Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Author(s): Iwamoto M, Wenning LA, Mistry GC, Petry AS, Liou SY, Ghosh K, Breidinger S, Azrolan N, Gutierrez MJ, Bridson WE, Stone JA, Gottesdiener KM, Wagner JA

Affiliation(s): Merck, Whitehouse Station, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com

Publication date & source: 2008-07-01, Clin Infect Dis., 47(1):137-40.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.